Publications by authors named "Wendy L Rasmussen"
Article Synopsis
- The study investigates the immunological responses to the modified vaccinia Ankara (MVA) smallpox vaccine using 523 participants who received either lyophilized or liquid MVA in different administration methods.
- Results showed that MVA triggered significant antibody production against several viral proteins, particularly after 28 and 42 days, with strong correlations between some antibody responses and plaque reduction neutralization tests (PRNT).
- The findings suggest that specific proteins from the MVA vaccine could be potential indicators of protection and may inform future vaccine development strategies.
Oligodeoxynucleotides containing CpG motifs (CpG ODN) can alter various immune cell subsets important in antibody therapy of malignancy. We undertook a phase I trial of CPG 7909 (also known as PF-3512676) in patients with previously treated lymphoma with the primary objective of evaluating safety across a range of doses, and secondary objectives of evaluating immunomodulatory effects and clinical effects. Twenty-three patients with previously treated non-Hodgkin lymphoma received up to 3 weekly 2-hour intravenous (IV) infusions of CPG ODN 7909 at dose levels 0.
View Article and Find Full Text PDFNF-kappaB essential modifier (NEMO), also known as IKK-gamma, is a member of the I-kappaB kinase complex responsible for phosphorylating I-kappaB, allowing the release and activation of NF-kappaB. Boys with an expressed NEMO mutation have an X-linked syndrome characterized by hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID). The immunophenotype resulting from NEMO mutation is highly variable, with deficits in both T and B cell responses.
View Article and Find Full Text PDF